Seaport Therapeutics, Inc. Common Stock

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tra

gurufocus.com - 2026-06-09 03:00:00

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.

businesswire.com - 2026-06-09 02:00:00

[url="]Seaport Therapeutics, Inc.[/url], (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and devel

gurufocus.com - 2026-06-08 08:00:00

[url="]Seaport Therapeutics, Inc.[/url], (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and devel

gurufocus.com - 2026-06-08 08:00:00

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.

businesswire.com - 2026-06-08 07:05:00

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers.

businesswire.com - 2026-06-08 07:00:00

[url="]Seaport Therapeutics, Inc.,[/url] (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and devel

gurufocus.com - 2026-06-01 08:00:00

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.

businesswire.com - 2026-06-01 07:00:00

Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Two IPOs are currently scheduled for the week ahead, though some smaller names may join the calendar late. Street research is expected for one company, and lock-up periods will be expiring for six companies.

seekingalpha.com - 2026-05-02 09:12:00

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.

proactiveinvestors.co.uk - 2026-05-01 04:47:20

Drug developer Seaport Therapeutics said on Thursday it had raised about $255 ​million in its upsized initial public ‌offering in the United States.

reuters.com - 2026-04-30 23:25:20

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering.

businesswire.com - 2026-04-30 21:55:00

Drug developer Seaport Therapeutics said on Monday it ​was aiming for a valuation of $912 ‌million in its initial public offering in the United States.

reuters.com - 2026-04-27 06:41:38